Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Climate disclosures are changing but climate risk is not
Recent changes to the CSRD and the pause to California’s SB 261 may remove or delay climate risk disclosure requirements, but the need to understand y
Changing internal models in a controlled environment
Capital models have advanced significantly since the early 2000s, but the increased complexity can slow decision-making and raise operational risks. T
MGAs, Market Cycles and Lloyd’s
In this episode of MGAA Conversations, host Mike Keating is joined by Rachel Turk, Chief of Market Performance at Lloyd’s of London, for an in-depth d

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.